Category Archives: BioUtah News
BioTech Nation Podcast: Fighting Inflammation, and Alzheimer’s: Dr. David Bearss, President & CEO Halia Therapeutics
BioTech Nation Podcast: Fighting Inflammation, and Alzheimer’s: Dr. David Bearss, President & CEO Halia Therapeutics
Jennifer Arnold, COO of Transit Scientific, promoted to President & CEO
Jennifer Arnold, COO of Transit Scientific, promoted to President & CEO
CancerVax Launches $5 Million Funding Round
Proceeds from the SEC qualified Reg A+ offering will allow the Company to continue work on its breakthrough cancer treatments
New ARUP University Business Unit Focuses on Patients and Services at University of Utah Health
Dan Albertson, MD, will serve as president of the University Business Unit.
VAREX ANNOUNCES CLOSING OF REVOLVING CREDIT FACILITY OF $155 MILLION
Varex Imaging has entered into a senior secured revolving credit agreement for an initial aggregate principal amount of up to $155 million.
New Survey Reveals Patients Receive Too Many Needlesticks
Most Americans Unaware of Challenges from Common Hospital Procedures
BD Named Among Fortune’s Most Innovative Companies
BD Named Among Fortune’s Most Innovative Companies
Dual 510(k) clearance and CLIA-waiver approval for the BIOFIRE® SPOTFIRE® R/ST Panel
Dual 510(k) clearance and CLIA-waiver approval for the BIOFIRE® SPOTFIRE® R/ST Panel
PhotoPharmics Launches Largest Phototherapy Trial for Parkinson’s Disease
Pivotal Trial for Improving Overall Function and Quality of Life
Spectrum Solutions® Releases the New SimplyPERIO™ Saliva Test Powered by SimplyTest®
Spectrum Solutions® Releases the New SimplyPERIO™ Saliva Test Powered by SimplyTest®
Seek Labs Appoints Renowned Life Sciences Innovator, Dr. Michael Paul, PhD, to Board of Directors
SALT LAKE CITY, UT, March 19, 2024 (Business Wire) – Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel CRISPR-based gene therapies, is pleased to announce the appointment of Michael Paul, PhD to its Board of Directors, effective March 18, 2024. With decades of experience in life sciences innovation, capital formation, […]
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market. U.S. patent […]
